What is the 13F Pro Quality Score for SLN?

13F Pro ranks Silence Therapeutics plc (SLN) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View SLN's current score at https://13fpro.ai/research/SLN (free sign-up required for the full ranking).

Which hedge funds own the most SLN stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of SLN include TCG Crossover Management,, Siren, L.L.C., Redmile Group,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/SLN as soon as new 13F filings post.

Where does 13F Pro source SLN data?

All Silence Therapeutics plc fundamentals and ownership data come directly from SEC EDGAR. Silence Therapeutics plc files with the SEC under CIK 1479615. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is SLN in?

Silence Therapeutics plc (SLN) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is SLN research updated on 13F Pro?

SLN's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Silence Therapeutics plc(SLN)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1479615 SLN stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $43.3M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

SLN Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Silence Therapeutics plc (SLN), a Healthcare sector company. SLN is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $43.3m in revenue. Based on the latest XBRL financial filings (Q1 2026), Silence Therapeutics plc reports quarterly revenue of $422.0K, net income of $-15.0M, free cash flow of $-15.6M. Top institutional holders of SLN by reported 13-F value include TCG Crossover Management,, Siren, L.L.C., Redmile Group,, based on the most recent SEC filings. SLN trades on the Nasdaq exchange and files with the SEC under CIK 1479615. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SLN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Silence Therapeutics plc directly from SEC EDGAR.

Revenue

Q1 2026

$422.0K

Net Income

Q1 2026

$-15.0M

Free Cash Flow

Q1 2026

$-15.6M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-98.7% YoY

$559.0KFY 2025

FY22 $21.7MFY23 $31.6MFY24 $43.3MFY25 $559.0K

Net Income

-95.6% YoY

$-88.6MFY 2025

FY22 $-50.3MFY23 $-54.2MFY24 $-45.3MFY25 $-88.6M

Operating Income

-43.8% YoY

$-91.1MFY 2025

FY22 $-61.0MFY23 $-64.4MFY24 $-63.3MFY25 $-91.1M

EPS (Diluted)

-90.9% YoY

$-0.63FY 2025

FY22 $-0.52FY23 $-0.49FY24 $-0.33FY25 $-0.63

Total Assets

-35.1% YoY

$131.4MFY 2025

FY22 —FY23 $119.4MFY24 $202.6MFY25 $131.4M

Op. Cash Flow

+7.9% YoY

$-62.3MFY 2025

FY22 $-57.0MFY23 $-49.5MFY24 $-67.6MFY25 $-62.3M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Revenue	$559.0K -98.7%	$43.3M +36.7%	$31.6M +46.1%	$21.7M	—
Net Income	$-88.6M -95.6%	$-45.3M +16.4%	$-54.2M -7.7%	$-50.3M	—
Operating Income	$-91.1M -43.8%	$-63.3M +1.7%	$-64.4M -5.5%	$-61.0M	—
EPS (Diluted)	$-0.63 -90.9%	$-0.33 +32.7%	$-0.49 +5.8%	$-0.52	—
Total Assets	$131.4M -35.1%	$202.6M +69.6%	$119.4M	—	—
Operating Cash Flow	$-62.3M +7.9%	$-67.6M -36.8%	$-49.5M +13.3%	$-57.0M	—

AI Insight: SLN Financial Trends

Silence Therapeutics is burning through equity rapidly, with book value collapsing from $134M in Q4 2024 to $49M in Q1 2026 — roughly 15 months of runway at current burn rates.

• Equity has eroded from $134M in Q4 2024 to $49M in Q1 2026, a $85M decline in five quarters with zero revenue.

• Net loss narrowed from -$29M in Q1 2025 to -$12M in Q4 2025 before re-widening to -$15M in Q1 2026.

• Operating cash outflow has ranged from -$11M to -$22M per quarter across the last five periods, showing no consistent improvement.

⚠ At Q1 2026 equity of $49M and quarterly cash burn of ~$16M, the balance sheet implies fewer than four quarters of runway without new financing.

⚠ Revenue remains $0M through Q1 2026 — any partnership milestone or licensing payment would be a critical inflection to monitor.

AI Insight: SLN Ratio Trends

Sparse data limits analysis, but ROE and ROA remain deeply negative, signaling persistent losses with no clear path to profitability visible in available metrics.

• ROE swung from -75.6% in Q4 2025 to -121.1% in Q1 2026, reversing a brief improvement.

• ROA deteriorated from -35.8% in Q4 2025 to -52.0% in Q1 2026, erasing Q4's relative strength.

• OpMargin, NPM, ROIC, and D/E are absent across all periods, severely limiting ratio-based analysis.

⚠ Q4 2025 showed the least-negative ROA (-35.8%) and ROE (-75.6%) — monitor whether that improvement was a one-off.

⚠ TTM ROA of -65.2% and ROE of -151.9% suggest annualized losses remain substantial; cash runway is a key risk.

Get alerted when SLN's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Silence Therapeutics plc including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of SLN

TCG Crossover Management, LLC
$16.0M3,033,560 sh
Siren, L.L.C.
$15.3M2,911,438 sh
Redmile Group, LLC
$11.4M2,164,777 sh
Nantahala Capital Management, LLC
$11.3M2,146,731 sh
CITADEL ADVISORS LLC
$6.5M1,234,807 sh
MILLENNIUM MANAGEMENT LLC
$5.7M1,074,191 sh
GREAT POINT PARTNERS LLC
$5.4M1,020,489 sh
Nextech Invest, Ltd.
$5.0M952,400 sh
TFG Asset Management GP Ltd
$3.3M630,161 sh
5AM Venture Management, LLC
$2.5M476,200 sh

Fund	Value	Shares
TCG Crossover Management, LLC	$16.0M	3,033,560
Siren, L.L.C.	$15.3M	2,911,438
Redmile Group, LLC	$11.4M	2,164,777
Nantahala Capital Management, LLC	$11.3M	2,146,731
CITADEL ADVISORS LLC	$6.5M	1,234,807
MILLENNIUM MANAGEMENT LLC	$5.7M	1,074,191
GREAT POINT PARTNERS LLC	$5.4M	1,020,489
Nextech Invest, Ltd.	$5.0M	952,400
TFG Asset Management GP Ltd	$3.3M	630,161
5AM Venture Management, LLC	$2.5M	476,200

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put SLN on your watchlist

Track score changes the day Silence Therapeutics plc files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is SLN a good stock to buy?

13F Pro's AI-powered analysis of Silence Therapeutics plc (SLN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SLN are available on the SLN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own SLN?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SLN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Silence Therapeutics plc's investment landscape.